Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 1,017–1,024 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
BioNTech SE Pumitamig - (China trial/ROSETTA HCC-206) 1L HCC Phase 2 Ongoing Intravenous Oncology
BioNTech SE BNT327-02 1-2L Metastatic Triple-negative breast cancer (TNBC) Phase 2 Data Released Intravenous Oncology
BioNTech SE Autogene cevumeran (BNT122/RO7198457) Adjuvant ctDNA+ stage II (high risk) / stage III colorectal cancer (CRC) Phase 2 Ongoing Intravenous Oncology
BioNTech SE BNT327-06 First line NSCLC Phase 2/3 Enrollment Initiation Intravenous Oncology
BioNTech SE Bivalent BNT162b2 Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine Phase 2/3 Ongoing Intramuscular COVID-19
BioNTech SE BNT161 Influenza Vaccine Phase 3 Intramuscular Immunology
BioNTech SE Autogene cevumeran (BNT122) 1L Metastatic Melanoma Phase 2 Ongoing Intravenous Oncology
BioNTech SE Trastuzumab pamirtecan (T-Pam) 2L+ HER2-expressing endometrial cancer Phase 2 Ongoing Intravenous Oncology